CG Oncology Inc. (CGON)
CGON price $62.32 +0.39 +0.63%
- Ticker
- CGON
- Price
- $62.32
- Change
- +0.39 +0.63%
- Market cap
- $5.52B
- P/E
- -22.94
- Forward P/E
- 23.44
- Sector
- Healthcare
- Industry
- Biotechnology
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to…